Items Tagged ‘GemRIS’

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative intent therapy. About Muscle Invasive Bladder Cancer Bladder cancer is the fifth most common neoplasm in industrialized countries, affecting […]